Fed Circuit refuses to revive Parkinson’s disease patent

Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

UCB challenges Teva generic drug application

3 July 2013 Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.

Americas

Teva infringed UCB patent, rules Fed Circuit

25 June 2019 The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.

More on this story

Americas

UCB challenges Teva generic drug application

3 July 2013 Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.

Americas

Teva infringed UCB patent, rules Fed Circuit

More on this story

Americas

UCB challenges Teva generic drug application

3 July 2013 Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.

Americas

Teva infringed UCB patent, rules Fed Circuit